

FORM 13-502F2
CLASS 2 REPORTING ISSUERS – PARTICIPATION FEE
MANAGEMENT CERTIFICATION

I, DHANJI, Salim Zulfikar, an officer of the reporting issuer noted below have examined this Form 13-502F2 (the **Form**) being submitted hereunder to the Ontario Securities Commission and certify that to my knowledge, having exercised reasonable diligence, the information provided in the Form is complete and accurate.

(s) DHANJI, Salim Zulfikar

19 Dec 2023

Name: DHANJI, Salim Zulfikar

Date:

Title: CEO

Reporting Issuer Name: ME Therapeutics Holdings Inc. / ME Therapeutics Holdings Inc. (000056569)

End date of previous financial year: 31 Aug 2023

Financial Statement Values:

(Use stated values from the audited financial statements of the reporting issuer as of the end of its previous financial year)

Retained earnings or deficit	\$ -7,240,866.00 (A)
Contributed surplus	\$ 3,208,468.00 (B)
Share capital or owners' equity, options, warrants and preferred shares (whether such shares are classified as debt or equity for financial reporting purposes)	\$ 4,523,869.00 (C)
Non-current borrowings (including the current portion)	\$ 40,000.00 (D)
Finance leases (including the current portion)	\$ 0.00 (E)
Non-controlling interest	\$ 0.00 (F)

Items classified on the statement of financial position as non-current liabilities (and not otherwise listed above)	\$ 0.00 (G)
Any other item forming part of equity and not set out specifically above	\$ 31,917.00 (H)
Capitalization for the previous financial year (Add items (A) through (H))	\$ 563,388.00
Participation Fee (From Appendix A of OSC Rule 13-502 <i>Fees</i> , select the participation fee beside the capitalization calculated above)	\$ 750.00
Late Fee, if applicable (As determined under section 8 of OSC Rule 13-502 <i>Fees</i>)	\$ 0.00
Total Fee Payable (Participation Fee plus Late Fee)	\$ 750.00